Background The interleukin-28B gene (IL28B) locus has been associated with host resistance to hepatitis C virus (HCV) infection and response to PEG-IFN/RBV treatment in western populations. This study was to determine whether this gene variant is also associated with spontaneous clearance of HCV infection, treatment response and IL-28B protein production in Chinese patients. Methods We genotyped IL28B genetic variations (rs12980275, rs8103142, rs8099917 and rs12979860) by pyrosequencing DNA samples from cohorts consisting of 529 subjects with persistent HCV infection, 196 subjects who cleared the infection, 171 healthy individuals and 235 chronic HCV patients underwent IFN/RBV treatment. The expression of IL-28B were measured by ELISA and RT-PCR. Results We found that the four IL28B variants were in complete linkage disequilibrium (r2 = 0.97–0.98). The rs12979860 CC genotype was strongly associated with spontaneously HCV clearance and successful IFN/RBV treatment compared to the CT/TT. IL-28B levels in persistent HCV patients were significantly lower than subjects who spontaneously resolved HCV and healthy controls and were also associated with high levels of ALT (alanine aminotransferase) and AST (aspartate aminotransferase). IL-28B levels were also significantly lower in individuals carrying T alleles than CC homozygous. Conclusions Thus, the rs12979860-CC variant upstream of IL28B gene is associated with spontaneous clearance of HCV, susceptible to IFN/RBV treatment and increased IL-28B levels in this Chinese population.
References
[1]
Lavanchy D (2009) The global burden of hepatitis C. Liver Int 29: Suppl 174–81.
[2]
NIH Consensus Statement on Management of hepatitis C: (2002) NIH Consens State Sci Statements 19(3): 1–46.
[3]
Manns M, McHutchison J, Gordon S, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferonalfa-2b plus ribavirin for initial treatment of chronic hepatitis C:a randomised trial. Lancet 358: 958–965.
[4]
Fried M, Shiffman M, Reddy K, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virusinfection. N Engl J Med 347: 975–982.
[5]
Hadziyannis S, Sette HJ, Morgan TR, Balan V, Diago M, et al. (2004) Peginterferon -alph2a and ribavirin combination therapy inchronic hepatitis C: a randomized study of treatment duration and ribavirindose. Ann Intern Med 140: 346–355.
[6]
Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, et al. (2006) The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144(10): 705–714.
[7]
Benvegnu L, Gios M, Boccato S, Alberti A (2004) Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut 53(5): 744–749.
[8]
Bruno S, Facciotto C (2008) The natural course of HCV infection and the need for treatment. Ann.Hepatol 7(2): 114–119.
[9]
Hwang SJ, Lee SD, Lu RH, Chu CW, Wu JC, et al. (2001) Hepatitis C viral genotype influences the clinical outcome of patients with acute posttransfusion hepatitis C. J Med Virol 65(3): 505–509.
[10]
Kenny-Walsh E (1999) Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 340(16): 1228–1233.
[11]
Dolganiuc A, Chang S, Kodys K, Mandrekar P, Bakis G, et al. (2006) Hepatitis C virus (HCV) core protein-induced, monocyte-mediated mechanisms of reduced IFN-alpha and plasmacytoid dendritic cell loss in chronic HCV infection. J Immunol 177(10): 6758–6768.
[12]
Marukian S, Jones CT, Andrus L, Evans MJ, Ritola KD, et al. (2008) Cell culture-produced hepatitis C virus does not infect peripheral blood mononuclear cells. Hepatology 48(6): 1843–1850.
[13]
Shiina M, Rehermann B (2008) Cell culture-produced hepatitis C virus impairs plasmacytoid dendritic cell function. Hepatology 47(2): 385–95.
[14]
Thio CL, Thomas DL, Carrington M (2000) Chronic viral hepatitis and the human genome. Hepatology 31(4): 819–827.
[15]
Missiha SB, Ostrowski M, Heathcote EJ (2008) Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors. Gastroenterology 134(6): 1699–1714.
[16]
Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD (1998) How cells respond to interferons. Annu Rev Biochem 67: 227–264.
[17]
Thomas DL, Thio CL, Martin MP, Qi Y, Ge D, et al. (2009) Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature 461(7265): 798–801.
[18]
Ank N, West H, Bartholdy C, Eriksson K, Thomsen AR, et al. (2006) Lambda interferon (IFN-lambda), a type III IFN, is induced by viruses and IFNs and displays potent antiviral activity against select virus infections in vivo. J Virol 80(9): 4501–9.
[19]
P. SheppardW. KindsvogelW. XuK. HendersonS. Schlutsmeyer et al 2003 IL-28, IL-29 and their class II cytokine receptor IL-28R. Nat Immunol 4 1 63 68
[20]
Sommereyns C, Paul S, Staeheli P, Michiels T (2008) IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathog 4(3): e1000017.
[21]
Kotenko SV, Gallagher G, Baurin VV, Lewis-Antes A, Shen M, et al. (2003) IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol 4(1): 69–77.
[22]
Doyle SE, Schreckhise H, Khuu-Duong K, Henderson K, Rosler R, et al. (2006) Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 44(4): 896–906.
[23]
Ank N, Iversen MB, Bartholdy C, Staeheli P, Hartmann R, et al. (2008) An important role for type III interferon (IFN-lambda/IL-28) in TLR-induced antiviral activity. (4): J Immunol 180. pp. 2474–2485.
[24]
Samuel CE (2001) Antiviral actions of interferons. Clin Microbiol Rev 14(4): 778–809.
[25]
Spann KM, KC Tran, PL Collins (2005) Effects of nonstructural proteins NS1 and NS2 of human respiratory syncytial virus on interferon regulatory factor 3, NF-kappaB, and proinflammatory cytokines. J Virol 79(9): 5353–5362.
[26]
Suppiah V, Moldovan M, Ahlenstiel G, Berg T, Weltman M, et al. (2009) IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy. Nat Genet 41(10): 1100–1104.
[27]
Tanaka Y, Nishida N, Sugiyama M, Kurosaki M, Matsuura K, et al. (2009) Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C. Nat Genet 41(10): 1105–1109.
[28]
Zechini B, Pasquazzi C, Aceti A (2004) Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: the role of serum aspartate transaminase in the evaluation of disease progression. Eur J Gastroenterol Hepatol 16(9): 891–896.
[29]
Rauch A, Gaudieri S, Thio C, Bochud PY (2009) Host genetic determinantsof spontaneous hepatitis C clearance. Pharmacogenomics 10: 1819–1837.
[30]
Aparicio E, Parera M, Franco S, Perez-Alvarez N, Tural C, et al. (2010) IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients. PLoS One. 5(10): e13771.
[31]
Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, et al. (2009) Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 461(7262): 399–401.
[32]
Rauch A, Kutalik Z, Descombes P, Cai T, Di Iulio J, et al. (2010) Genetic variation in IL28B is associated with chronic hepatitis C and treatment failure: a genome-wide association study. Gastroenterology 138(4): 1338–1345.
[33]
Hepburn MJ, Hepburn LM, Cantu NS, Lapeer MG, Lawitz EJ (2004) Differences in treatment outcome for hepatitis C among ethnic groups. Am J Med 117(3): 163–168.
[34]
Ghany MG, Strader DB, Thomas DL, Seeff LB (2009) Diagnosis, management, and treatment of hepatitis C: An update. Hepatology 49(4): 1335–1374.
[35]
Yu ML, Chuang WL (2009) Treatment of chronic hepatitis C in Asia: when East meets West. J Gastroenterol Hepatol 24: 336–345.
[36]
Huang CF, Yang JF, Huang JF, Dai CY, Chiu CF, et al. (2010) Early identification of achieving a sustained virological response in chronic hepatitis C in patients without arapid virological response.J Gastroenterol Hepatol 25: 758–765.
[37]
Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, et al. (2003) Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatoloty 38: 645–652.
[38]
Sarasin-Filipowicz M, Oakeley EJ, Duong FH, Christen V, Terracciano L, et al. (2008) Interferon signaling and treatment outcome in chronic hepatitis C. Proc Natl Acad Sci U S A 105: 7034–7039.
[39]
Langhans B, Kupfer B, Braunschweiger I, Arndt S, Schulte Wetal (2011) Interferon-lambda serum levels in hepatitis C. J Hepatol 54(5): 859–865.
[40]
Rauch A, Rohrbach J, Bochud PY (2010) The recent breakthroughs in the understanding of host genomics in hepatitis C. Eur J Clin Invest 40(10): 950–959.